'For
the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 10.14% to Rs 12380.7 crore compared to quarter ended Dec 2022. Operating profit margin has jumped from 26.72% to 28.08%, leading to 15.75% rise in operating profit to Rs 3,476.83 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.63% to 14.07%. Purchase of finished goods cost fell from 7.93% to 6.56%. Employee cost increased from 18.21% to 19.45%. Other expenses rose from 30.37% to 31.31%. Other income rose 43.89% to Rs 250.2 crore. PBIDT rose 17.29% to Rs 3727.03 crore. Provision for interest fell 24.79% to Rs 34.73 crore.
PBDT rose 17.91% to Rs 3692.3 crore. Provision for depreciation fell 5.73% to Rs 622.14 crore.
Profit before tax grew 24.22% to Rs 3,07...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Aug-2024)
AIA Engineering
Net down 5% on lower sales
-
(17-Aug-2024)
Voltas
Net jump 159% on good operating show
-
(17-Aug-2024)
ABB India
Net up 50% on good operating show
-
(17-Aug-2024)
NHPC
Sales down 2%, net down 1%
|
|